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Background
A major roadblock to understanding HIV-1 structure and
function, and the development of an effective vaccine, is
the lability of the infectious Env trimer complex. Despite
several methodologies, including disulfide bonds, chemi-
cal cross-linking and truncation, this lability has made it
difficult to obtain detailed information about contact
points within the Env spike.
Methods
Using the technology pioneered by Peter Schultz, an
unnatural amino acid with novel reactivity, including
ketones, azides, and actelyenes groups, can be site-specif-
ically incorporated into gp120. Such an unnatural amino
acid can be subsequently derivatized with high efficiency
and selectivity for labeling purposes.
Results
We are working towards co-translationally introducing an
unnatural amino acid at a defined site in gp120. An
orthogonal suppressor transfer RNA – aminoacyl-tRNA
synthetase pair has been developed to genetically encode
an unnatural amino acid in response to an amber non-
sense codon in the HIV-1 glycoprotein.
Conclusion
Integration of this unnatural amino acid into the HIV-1
glycoprotein will provide a powerful tool to map biomo-
lecular interactions within the Env spike.
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